You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Bcr-Abl Kinase Inhibitors

Showing 1 - 25 of 5,933
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Myeloproliferative Tumor, Chronic Phase Chronic Myelogenous Leukemia, Chronic Myeloid Leukemia Trial in San Francisco (Online

Recruiting
  • Myeloproliferative Neoplasm
  • +2 more
  • Online Mindfulness Meditation
  • Internet-Based Webinars
  • San Francisco, California
    University of California San Francisco
Aug 9, 2022

Tyrosine Kinase Inhibitors, Chronic Myeloid Leukemia Trial in Poitiers (treatment of TKI in CML)

Not yet recruiting
  • Tyrosine Kinase Inhibitors
  • Chronic Myeloid Leukemia
  • treatment of TKI in CML
  • Poitiers, France
    Chu Poitiers
Feb 21, 2023

CML Trial in Ciudad Autonoma de Buenos Aire (Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment)

Recruiting
  • CML
  • Discontinuing treatment with Tyrosine Kinase Inhibitor after enrolment
  • Ciudad Autonoma de Buenos Aire, Ciudad Autonoma De Buenos Aires, Argentina
    FUNDALEU
Jun 29, 2023

Olverembatinib, Chronic Myeloid Leukemia, Chronic Phase, Tyrosine Kinase Inhibitors Trial in Shenzhen (olverembatinib)

Recruiting
  • Olverembatinib
  • +2 more
  • Shenzhen, Guangdong, China
    Shenzhen Second People's Hospital
Jul 26, 2022

Information of Ponatinib, Bosutinib, Imatinib, Dasatinib and

Completed
  • Leukemia
  • No Intervention
  • Cambridge, Massachusetts
    Takeda
Feb 28, 2023

Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia Trial in Houston (Asciminib)

Recruiting
  • Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia
  • Houston, Texas
    M D Anderson Cancer Center
Feb 1, 2022

TyrosIne Kinase Inhibitors in Chronic Myeloid Leukemia: Efficacy

Recruiting
  • Chronic Myeloid Leukemia
  • Pisa, Italy
  • +1 more
Jan 4, 2022

Study Conducted Among Patients With CML

Completed
  • Chronic Myeloid Leukemia
  • Tyrosine Kinase Inhibitors (TKIs)
  • East Hanover, New Jersey
    Novartis Investigative Site
Jul 25, 2022

Leukemia, Chronic Myelogenous Trial in China (asciminib, best available treatment)

Recruiting
  • Leukemia, Chronic Myelogenous
  • Chongqing City, Chongqing, China
  • +23 more
Jan 18, 2023

Ovarian Reserve and Fertility in Chronic Myeloid Leukemia or

Recruiting
  • Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • +2 more
  • Cytology Specimen Collection Procedure
  • +3 more
  • Los Angeles, California
    USC / Norris Comprehensive Cancer Center
Nov 16, 2021

Chronic Myeloid Leukemia in Chronic Phase Trial in Belgium, Germany (LBH589)

Terminated
Has Results
  • Chronic Myeloid Leukemia in Chronic Phase
  • Bruxelles, Belgium
  • +9 more
Jul 14, 2021

Chronic Myeloid Leukemia, Chronic Phase, Withdrawal;Drug Trial in Czechia (Imatinib withdrawal, Dasatinib, Nilotinib)

Recruiting
  • Chronic Myeloid Leukemia, Chronic Phase
  • Withdrawal;Drug
  • Imatinib withdrawal
  • +2 more
  • Brno, Czechia
  • +7 more
Aug 24, 2022

Treatment Free Remission, Chronic Myeloid Leukemia Trial in Turin

Recruiting
  • Treatment Free Remission
  • Chronic Myeloid Leukemia
    • Turin, Italy
      Division of Hematology-AO Mauriziano Hospital, University of Tur
    Nov 17, 2021

    Leukemia,Myeloid, Chronic Trial in France (Blood and bone marrow sample)

    Not yet recruiting
    • Leukemia,Myeloid, Chronic
    • Blood and bone marrow sample
    • Annecy, France
    • +15 more
    Nov 10, 2023

    The Life After Stopping Tyrosine Kinase Inhibitors Study

    Completed
    • Leukemia, Myeloid, Chronic
    • Imatinib (Stopping their TKI)
    • +3 more
    • San Francisco, California
    • +15 more
    Jan 3, 2023

    Treatment, Stem Cell Transplantation Trial in Italy (Nilotinib, Imatinib)

    Completed
    • Treatment
    • Stem Cell Transplantation
    • Ancona, Italy
    • +34 more
    Oct 10, 2022

    Myeloid Leukemia, Philadelphia Positive Trial in Worldwide (Asciminib Pediatric formulation group, Asciminib Adult formulation

    Recruiting
    • Myeloid Leukemia, Philadelphia Positive
    • Asciminib Pediatric formulation group
    • Asciminib Adult formulation group
    • Boston, Massachusetts
    • +24 more
    Jan 17, 2023

    Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelogenous Leukemia, BCR-ABL1 Positive in Remission, Minimal Residual

    Terminated
    • Chronic Myelogenous Leukemia, BCR-ABL1 Positive
    • +3 more
    • Houston, Texas
      M D Anderson Cancer Center
    Dec 1, 2020

    Myeloid Leukemia, Chronic Trial in Germany (dasatinib (SPRYCEL®))

    Active, not recruiting
    • Myeloid Leukemia, Chronic
    • dasatinib (SPRYCEL®)
    • Aachen, Germany
    • +52 more
    Jun 1, 2022

    Chronic Myelogenous Leukemia Trial in Worldwide (ABL001 40mg BID, ABL001 80mg QD, ABL001 200mg QD)

    Recruiting
    • Chronic Myelogenous Leukemia
    • ABL001 40mg BID
    • +2 more
    • Caba, Buenos Aires, Argentina
    • +53 more
    Jan 27, 2023

    Leukemia, Myeloid, Chronic Trial in Germany, United States (LBH589)

    Terminated
    Has Results
    • Leukemia, Myeloid, Chronic
    • Duarte, California
    • +25 more
    Jul 14, 2021

    Tyrosine Kinase Inhibitor in Chronic Myeloid Leukemia

    Not yet recruiting
    • Tyrosine Kinase Inhibitor
    • +2 more
      • Taipei, Taiwan
        National Taiwan University Hospital
      Feb 17, 2022

      Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive,

      Completed
      • Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
      • +4 more
      • Eltrombopag Olamine
      • Houston, Texas
        M D Anderson Cancer Center
      Jan 4, 2022

      Condition Vasoregulation Function Endothelium in CML Getting TKI

      Recruiting
      • Chronic Myeloid Leukaemia
      • taking blood for the study of biochemical parameters and the study of microcirculation using the method of laser Doppler flowmetry
      • Moscow, Russian Federation
      • +1 more
      Jan 11, 2023

      Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase Chronic Myelogenous Leukemia Trial in Philadelphia (Text

      Recruiting
      • Chronic Myelogenous Leukemia, BCR-ABL1 Positive
      • Chronic Phase Chronic Myelogenous Leukemia
      • Text Message-Based Navigation Intervention
      • Survey Administration
      • Philadelphia, Pennsylvania
        Sidney Kimmel Cancer Center at Thomas Jefferson University
      Apr 7, 2022